We are proud to announce the launch of EarlyTect® BCD! Learn more here.

Promis Dx EarlyTect® BCD Delivers High Accuracy for Bladder Cancer Diagnosis

Irvine, California, January 30, 2025

Promis Dx’s EarlyTect® BCD, a urinary DNA methylation test, demonstrated outstanding performance in detecting bladder cancer, especially high-grade and invasive cases. The test achieved a sensitivity of 89.2% for high-grade or invasive bladder cancer and 78.1% for overall bladder cancer, ensuring reliable detection of aggressive tumors. Its specificity reached 87.8% for no high-grade or invasive cancer and 88.8% for no bladder cancer, reducing false positives effectively. The test also showed a positive predictive value (PPV) of 61.3% for high-grade or invasive cancer and 63.3% for overall bladder cancer, while maintaining an impressive negative predictive value (NPV) of 97.6%, minimizing the chances of missed diagnoses. With its high accuracy, EarlyTect® BCD offers a noninvasive, reliable diagnostic alternative, potentially transforming early bladder cancer detection and improving patient outcomes. Promis Dx continues its mission to advance innovative diagnostic technologies that support early cancer detection and better clinical decision-making.

Key EarlyTect® BCD Results:

  • Sensitivity:
    • 89.2% for high-grade or invasive bladder cancer
    • 78.1% for overall bladder cancer
  • Specificity:
    • 87.8% for no high-grade or invasive bladder cancer
    • 88.8% for no bladder cancer
  • Positive Predictive Value (PPV):
    • 61.3% for high-grade or invasive bladder cancer
    • 63.3% for overall bladder cancer
  • Negative Predictive Value (NPV):
    • 97.6% for high-grade or invasive bladder cancer
    • 94.2% for overall bladder cancer

 

Clinical Implication:
With its high sensitivity and excellent negative predictive value, EarlyTect® BCD effectively detects high-risk bladder cancer while reducing the likelihood of false negatives. It offers a reliable, noninvasive solution for early diagnosis and monitoring.

Promis Dx remains committed to improving outcomes through innovative diagnostic technologies.

For a more detailed article, read here: https://jamanetwork.com/journals/jamaoncology/article-abstract/2829522